Actelion Ltd (ALIOF) 122.2400 $ALIOF Global Gaucher's

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actelion Ltd (ALIOF) 122.2400 $ALIOF

Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 7.58 (+0.71)

Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 23.74 (+0.26), IMMU: 2.17 (+0.12), AMGN: 149.59 (-0.31), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), JNJ: 95.37 (+0.29), ARGS: 5.80 (-0.18), ANTH: 6.12 (+0.12), ABBV: 55.64 (-0.40), CBMG: 18.62 (+0.05), KPTI: 11.75 (+0.04), CELGZ: 1.74 (+0.04)

KYTHERA Files IND Application for Male Hair Loss Treatment
Zacks Equity Research - Zacks Investment Research - Wed Sep 23, 4:05PM CDT
KYTHERA (KYTH) has filed an investigational new drug application for KYTH-105 for the treatment of male pattern hair loss.
AGN: 274.84 (-1.32), GILD: 100.65 (-0.16), KYTH: 74.98 (-0.01)

Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Respiratory Society (ERS) Congress 2015
Thomson Reuters ONE - Wed Sep 23, 12:00AM CDT
Actelion Pharmaceuticals Ltd / Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Respiratory Society (ERS) Congress 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Biotech Poised to Rebound: 5 Growth Picks
Swarup Gupta - Zacks Investment Research - Tue Sep 15, 10:36AM CDT
The NASDAQ Biotechnology Index has already embarked upon a recovery this month, increasing 3.3%, and is poised for further gains.
RGEN: 25.28 (+0.76), ZSPH: 66.89 (+1.72), CLVS: 93.60 (+3.62), GILD: 100.65 (-0.16), VTAE: 13.00 (+0.10), VVUS: 2.00 (unch), AKBA: 10.56 (+0.63), BMY: 61.44 (+0.93), AFFX: 8.71 (-0.04), REGN: 503.92 (+12.71)

Actelion Down on Confirmed Discussions with ZS Pharma
Zacks Equity Research - Zacks Investment Research - Mon Sep 14, 4:05PM CDT
Actelion Ltd.'s (ALIOF) shares fell 3.2% following the company's confirmation on the news that it has initiated preliminary discussions with ZS Pharma.
VRX: 175.94 (+4.77), ZSPH: 66.89 (+1.72), RLYP: 18.40 (+0.12), SHPG: 200.90 (-1.85)

ZS Pharma Corporate Statement
GlobeNewswire - Thu Sep 10, 4:31PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), today confirmed that it has participated in preliminary discussions with Actelion Ltd. (OTC:ALIOF) regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. These discussions may or may not lead to any transaction. ZS Pharma does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required.
ZSPH: 66.89 (+1.72)

ACTELION STATEMENT
Thomson Reuters ONE - Thu Sep 10, 4:15PM CDT
Actelion Pharmaceuticals Ltd / ACTELION STATEMENT . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
ZSPH: 66.89 (+1.72)

Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin
Thomson Reuters ONE - Sat Sep 05, 1:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endothelin . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Intercept's (ICPT) OCA Under Priority Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 4:54PM CDT
Intercept Pharmaceuticals' (ICPT) NDA for obeticholic acid has been accepted by the FDA for priority review for the treatment of primary biliary cirrhosis.
GILD: 100.65 (-0.16), ICPT: 181.90 (-8.81), REGN: 503.92 (+12.71)

Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities 2015-2019
M2 - Tue Sep 01, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43kmtp/global_pulmonary) has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)" report to their offering. The report titled Global PAH Market: Trends and Opportunities (2015-2019), analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs. The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report. The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments. Company Coverage - Actelion Limited - United Therapeutics Limited - SteadyMed Limited PAH Drug Mechanism - Endothelin Receptor Antagonists (ERA) - PDE 5 Inhibitors - Prostacyclins - sGC Stimulator Key Topics Covered: 1. Executive Summary 2. Pulmonary Arterial Hypertension (PAH): An Introduction 3. Global Pulmonary Arterial Hypertension (PAH) Market: An Analysis 4. Global PAH Market Share: An Analysis 5. Patch Pump Technology Market: An Analysis 6. Market Dynamics:Global PAH Market 7. Competitive Landscape:Global PAH Market 8. Company Profiles:Global PAH Market For more information visit http://www.researchandmarkets.com/research/43..._pulmonary
UTHR: 123.59 (-1.69), STDY: 2.98 (-0.02)

Seres (MCRB) Up on Orphan Drug Status for Lead Candidate
Zacks Equity Research - Zacks Investment Research - Mon Aug 24, 1:50PM CDT
Seres Therapeutics (MCRB) announced that SER-109 received orphan drug status from the FDA for the prevention of recurrent Clostridium difficile infection.
GILD: 100.65 (-0.16), MCRB: 29.80 (+0.58), REGN: 503.92 (+12.71)

Seattle Genetics' Adcetris Label Expanded in the U.S.
Zacks Equity Research - Zacks Investment Research - Tue Aug 18, 3:35PM CDT
Seattle Genetics' (SGEN) Adcetris receives FDA nod for Hodgkin lymphoma in patients running a high risk of relapse or progression in post-transplant setting.
SGEN: 39.38 (+0.87), AMAG: 40.06 (+1.32)

Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 29.89 (-0.22), CVD: 106.42 (-0.71), JNJ: 95.37 (+0.29), ABBV: 55.64 (-0.40), ABT: 41.89 (+0.73), CBSTZ: 0.06 (unch), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), GRFS: 32.59 (+0.13), GILD: 100.65 (-0.16), BAX: 33.21 (-0.04), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.29 (+0.10), ADRO: 22.06 (+0.32), AMBX: (), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), AMPE: 3.04 (+0.05), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), AAAP: ()

Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 7.00 (+0.02), CNAT: 4.21 (-0.06), CLDN: 1.12 (+0.03), LLY: 86.14 (+2.37), CLSN: 1.84 (+0.14), ASND: 17.24 (+0.05), ABBV: 55.64 (-0.40), ANAC: 115.06 (+2.13), ARNA: 2.19 (+0.14)

Systemic Lupus Erythematosus: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2p7pm/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects Companies Mentioned - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kymab Limited - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - National Pharmaceutical Corp. - Neovacs SA - Nippon Chemiphar Co., Ltd. - Padlock Therapeutics, Inc. - Pfizer Inc. - Plexxikon Inc. - RedHill Biopharma Ltd. - Redx Pharma Ltd - Resolve Therapeutics, LLC - Sanofi - Sarepta Therapeutics, Inc. - SATT Conectus Alsace SAS - SBI Biotech Co., Ltd. - Seattle Genetics, Inc. - Takeda Pharmaceutical Company Limited - Therapix Biosciences Ltd - UCB S.A. - Xencor, Inc. - XTL Biopharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/c2...emic_lupus
RDHL: 12.80 (+0.53), JNJ: 95.37 (+0.29), ANTH: 6.12 (+0.12), SRPT: 37.09 (-0.72), ABBV: 55.64 (-0.40), XNCR: 12.28 (-0.13), CBMG: 18.62 (+0.05), MGNX: 23.74 (+0.26), IMMU: 2.17 (+0.12), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), ARGS: 5.80 (-0.18), SGEN: 39.38 (+0.87), CELGZ: 1.74 (+0.04)

Mallinckrodt to Acquire Therakos, Boost Hospital Business
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 2:55PM CDT
Mallinckrodt (MNK) entered into a definitive agreement to acquire Therakos, Inc. from The Gores Group in a transaction valued at roughly $1.325 billion.
MNK: 66.73 (-1.81), VRX: 175.94 (+4.77), CORT: 3.74 (-0.05)

Catalyst Pharmaceuticals' Loss Wider Y/Y, Firdapse in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 10:44AM CDT
Catalyst Pharmaceuticals (CPRX) reported second-quarter 2015 loss of 6 cents per share, wider than the Zacks Consensus Estimate of a loss of 7 cents.
VRX: 175.94 (+4.77), CPRX: 3.18 (+0.10), CORT: 3.74 (-0.05)

Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 9:50AM CDT
Merrimack Pharmaceuticals (MACK) reported second-quarter 2015 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents.
MACK: 9.60 (+0.17), BXLT: 31.03 (-0.06), CORT: 3.74 (-0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 143

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 45

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 116

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 35

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 10

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Industrial Production Unexpectedly Declines, Impacting Growth

Updated Category News Views 62

U.S. Industrial Production Experiences a Notable Decline The latest report reveals that U.S. industrial production has faced an unexpected decline, recorded at -0.3%. This drop highlights the ongoing struggles within the manufacturing, mining, and utility sectors. Disappointing Performance Against Expectations When comparing the -0.3% figure to a predicted decrease of...

Continue Reading
MAXHUB Partners with Microsoft to Enhance Teams Rooms Experience

Updated Category News Views 363

MAXHUB Collaborates with Microsoft to Enhance Teams In an exciting development within the tech landscape, MAXHUB is teaming up with Microsoft in an initiative aimed at improving the security and reliability of Microsoft Teams Rooms. This partnership aligns with MAXHUB's vision of leading in integrated commercial display and unified communications solutions, providing...

Continue Reading
US Dollar Strengthens While Global Markets Face Turmoil

Updated Category News Views 486

US Dollar's Rise Amid Trade Tensions In an unexpected turn of events, the US dollar has extended its gains following President Trump's announcement of new tariffs. As the global markets react to these developments, we dive into the implications for various economies and asset classes. The latest updates indicate that the 25% tariffs on imports from Canada and Mexico,...

Continue Reading
Understanding Your Rights as a Perrigo Company Shareholder

Updated Category News Views 135

Understanding Your Rights as a Perrigo Company Shareholder Shareholders of Perrigo Company plc (NYSE: PRGO) should stay informed about recent developments regarding potential securities law violations. The underlying issues stem from allegations that the company misled investors regarding its infant formula business, which has drawn significant scrutiny. Allegations...

Continue Reading
Spring Surprises: White Castle Unveils Exciting Deals Ahead

Updated Category News Views 521

Spring Promotions at White Castle As the season transforms, White Castle, the pioneering fast-food restaurant known for its Original Slider, unveils enticing deals for its loyal customers. Embracing longer days and warmer weather, the company is determined to deliver exceptional savings for all cravings this spring. Celebrating with Value-Driven Offers White Castle is...

Continue Reading